SG149867A1 - Selective estrogen receptor modulators for the treatment of vasomotor symptoms - Google Patents

Selective estrogen receptor modulators for the treatment of vasomotor symptoms

Info

Publication number
SG149867A1
SG149867A1 SG200900414-4A SG2009004144A SG149867A1 SG 149867 A1 SG149867 A1 SG 149867A1 SG 2009004144 A SG2009004144 A SG 2009004144A SG 149867 A1 SG149867 A1 SG 149867A1
Authority
SG
Singapore
Prior art keywords
treatment
estrogen receptor
receptor modulators
selective estrogen
vasomotor symptoms
Prior art date
Application number
SG200900414-4A
Other languages
English (en)
Inventor
Robert Dean Dally
Jeffrey Alan Dodge
Scott Alan Frank
Ronald Jay Hinklin
Timothy Alan Shepherd
Owen Brendan Wallace
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG149867A1 publication Critical patent/SG149867A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/092Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/18Ring systems of four or more rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG200900414-4A 2004-01-22 2005-01-18 Selective estrogen receptor modulators for the treatment of vasomotor symptoms SG149867A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53844204P 2004-01-22 2004-01-22
US53834204P 2004-01-22 2004-01-22

Publications (1)

Publication Number Publication Date
SG149867A1 true SG149867A1 (en) 2009-02-27

Family

ID=34830456

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200900414-4A SG149867A1 (en) 2004-01-22 2005-01-18 Selective estrogen receptor modulators for the treatment of vasomotor symptoms

Country Status (20)

Country Link
US (2) US20090023917A1 (https=)
EP (1) EP1709021B1 (https=)
JP (1) JP4909086B2 (https=)
KR (2) KR100849559B1 (https=)
CN (1) CN102250042A (https=)
AT (1) ATE476428T1 (https=)
AU (1) AU2005207821B2 (https=)
BR (1) BRPI0506721A (https=)
CA (1) CA2551956C (https=)
CR (1) CR8517A (https=)
DE (1) DE602005022673D1 (https=)
EA (2) EA012262B1 (https=)
EC (1) ECSP066711A (https=)
ES (1) ES2347973T3 (https=)
IL (1) IL176738A0 (https=)
MA (1) MA28436B1 (https=)
NO (1) NO20063760L (https=)
SG (1) SG149867A1 (https=)
UA (1) UA85862C2 (https=)
WO (1) WO2005073204A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002490A2 (en) 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
US10144736B2 (en) * 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
CA2738878C (en) * 2008-09-29 2013-08-13 Eli Lilly And Company Selective estrogen receptor modulator for the treatment of osteoarthritis
US20100087402A1 (en) * 2008-09-29 2010-04-08 Vivus, Inc. Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
HUE030072T2 (en) 2010-05-12 2017-04-28 Radius Health Inc Therapeutic prescriptions
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
FR3014437B1 (fr) * 2013-12-05 2016-12-23 Servier Lab Nouveau procede de synthese de l'agomelatine
FR3014434B1 (fr) * 2013-12-05 2015-12-25 Servier Lab Nouveau procede de synthese du 7-methoxy-naphtalene-1-carbaldehyde et application a la synthese de l'agomelatine
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
ES3055185T3 (en) 2014-03-28 2026-02-10 Univ Duke Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
US9670205B2 (en) 2015-03-04 2017-06-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
MX389702B (es) 2016-06-22 2025-03-20 Ellipses Pharma Ltd Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
AU2017318601B2 (en) 2016-09-02 2020-09-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ,インコーポレイテッド Rad1901-2hclの多形性形態
CN108675999B (zh) * 2018-05-09 2021-03-16 浙江农林大学暨阳学院 一种醋酸铜催化制备8-(9-亚砜基-10-二氢菲)喹啉类化合物的方法
MX2020013713A (es) 2018-07-04 2021-03-02 Radius Pharmaceuticals Inc Formas polimorficas de rad1901-2hcl.
CN112424205B (zh) * 2018-07-12 2023-10-31 伊莱利利公司 选择性的雌激素受体降解剂
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
EP3924328A1 (en) 2019-02-12 2021-12-22 Radius Pharmaceuticals, Inc. Processes and compounds
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
TWI894443B (zh) 2021-03-16 2025-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
CA3243621A1 (en) 2022-02-01 2023-08-10 Eli Lilly And Company METHODS FOR PREPARING SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENTS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5726186A (en) * 1995-09-08 1998-03-10 Eli Lilly And Company Pentacyclic compounds, intermediates, processes, compositions, and methods
ID19392A (id) * 1996-08-29 1998-07-09 Lilly Co Eli Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan
CA2213810C (en) * 1996-08-29 2006-06-06 Lewis Dale Pennington Benzo¬b|thiophene compounds, intermediates, processes, compositions and methods
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
CA2217810A1 (en) * 1996-10-10 1998-04-10 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods
CA2298651A1 (en) * 1997-08-07 1999-02-18 Jeffrey Alan Dodge 1-¬4-(substituted alkoxy)benzyl|naphthalene compounds having estrogen inhibitory activity
EA008024B1 (ru) * 2002-07-22 2007-02-27 Эли Лилли Энд Компани Селективные модуляторы эстрогенных рецепторов, содержащие фенилсульфонильную группу

Also Published As

Publication number Publication date
US20090023917A1 (en) 2009-01-22
KR101008804B1 (ko) 2011-01-14
CR8517A (es) 2006-12-01
EA012262B1 (ru) 2009-08-28
KR20060129277A (ko) 2006-12-15
KR100849559B1 (ko) 2008-07-31
US20110281847A1 (en) 2011-11-17
US8217032B2 (en) 2012-07-10
MA28436B1 (fr) 2007-02-01
BRPI0506721A (pt) 2007-05-02
CA2551956C (en) 2013-05-07
EA016613B1 (ru) 2012-06-29
ECSP066711A (es) 2006-10-31
AU2005207821A1 (en) 2005-08-11
EA200900586A1 (ru) 2009-08-28
AU2005207821B2 (en) 2011-02-10
CN102250042A (zh) 2011-11-23
KR20080016755A (ko) 2008-02-21
NO20063760L (no) 2006-10-16
CA2551956A1 (en) 2005-08-11
ATE476428T1 (de) 2010-08-15
WO2005073204A1 (en) 2005-08-11
DE602005022673D1 (de) 2010-09-16
UA85862C2 (uk) 2009-03-10
JP4909086B2 (ja) 2012-04-04
JP2007519721A (ja) 2007-07-19
ES2347973T3 (es) 2010-11-26
IL176738A0 (en) 2006-10-31
EP1709021B1 (en) 2010-08-04
EA200601353A1 (ru) 2007-02-27
EP1709021A1 (en) 2006-10-11

Similar Documents

Publication Publication Date Title
SG149867A1 (en) Selective estrogen receptor modulators for the treatment of vasomotor symptoms
NL301145I1 (https=)
IL176706A0 (en) Azadecalin glucocorticoid receptor modulators
IL177982A0 (en) Fused ring azadecalin glucocorticoid receptor modulators
ZA200704223B (en) Estrogen receptor modulators
IL182829A0 (en) Estrogen receptor modulators
SG152239A1 (en) Compounds for proteasome enzyme inhibition
GB0400440D0 (en) Receptor modulators
PL2031063T3 (pl) Modulatory receptorów węchowych
TW200617019A (en) A process for the preparation of 7α-alkylated 19-norsteroids
WO2005105785A3 (en) Indole derivatives for treatment of obesity
PL376803A1 (pl) Nowe pochodne tetracykliczne zawierające heteroatomy, jako selektywne modulatory receptora estrogenowego
IL191710A0 (en) Glucocorticoid receptor modulators as antiinflammatory agents
ATE399776T1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
IL177957A0 (en) Bazedoxifene ascorbate as selective estrogen receptor modulator
EP1733781A4 (en) APPARATUS FOR CONCENTRATING METHANE GAS
IL177936A0 (en) Process for cross coupling indoles
ZA200800690B (en) Non-steroidal progesterone receptor modulators
SG142306A1 (en) Methods for neuroprotection
IL164169A0 (en) Non-steroidal progesterone receptor modulators
MX2008000874A (es) Metodos y composiciones para anticoncepcion de emergencia utilizando antagonistas del receptor de endotelina.
NO20091016L (no) Pyridooksazepin-progesteron reseptormodulatorer
HK1096094A (en) Selective estrogen receptor modulators for the treatment of vasomotor symptoms
HU0501174D0 (en) Apparatus for introducing organwind
AU2008248873A8 (en) New progesterone receptor modulators